The company announced on Thursday that the U.S. Food and Drug Administration has cleared the use of Emergent BioSolutions’ (EBS.N) anthrax vaccine in individuals ages 18 through 65.
Cyfendus, a vaccination that must be taken with antibiotics, has been approved for use if exposure to a specific type of bacteria has been suspected or proven.
The bacteria Bacillus anthracis can cause the potentially fatal infectious illness anthrax. Although people who come into contact with the spores can contract the infection, the bacteria most frequently infect hoofed animals like goats.
Since 2019, Emergent has been supplying the U.S. Department of Health and Human Services with Cyfendus under a pre-emergency use authorization status. The business said it would keep collaborating with the American government to make the switch to post-approval procurement.
